MFAP4 and prostate carcinoma: The apparently complex role of MFAP4 in cancers is further supported by the Human Protein Atlas database [65] showing clinical survival analyses in which local tumor MFAP4 expression can be either favorable or unfavorable depending on the cancer type (unfavorable: cervical, endometrial, glioma, melanoma, ovarian, renal, stomach, thyroid and urothelial cancer; favorable: breast, head and neck, liver, lung, pancreatic and prostate cancer) [109].